About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals is a publicly listed company based in Buffalo (United States) founded in 2014. Breakthrough therapies are developed for blood diseases and infections. It operates on a HealthTech model. Hemogenyx Pharmaceuticals has raised $1 million across 8 funding rounds from investors including Prevail Partners, MINT Capital and 43North. The company has 22 employees. Hemogenyx Pharmaceuticals offers products and services including Breakthrough Therapies. Its focus areas include Biotechnology and Blood Disease Treatments. Its legal entity is Hemogenyx Pharmaceuticals plc. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
Hemogenyx Pharmaceuticals is focused on the development of innovative therapies for the treatment of life-threatening blood diseases and viral infections. Research and solutions are targeted at addressing critical medical needs in the healthcare sector, particularly in biotechnology. The company operates with facilities in both the United Kingdom and the United States to advance its pipeline of therapeutic products.
- Headquarters Buffalo, United States
- Employees 22
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website hemogenyx.com
- Social X Facebook YouTube
- Legal Name Hemogenyx Pharmaceuticals Plc
- Net Profit-$13.14 M (USD)-73.7as on Dec 31, 2025
- EBITDA-$5.48 M (USD)19.96as on Dec 31, 2025
- Total Equity Funding$1M (USD)
in 8 rounds
- Latest Funding Round$3.41M (USD), Post-IPO
Feb 2026
- InvestorsPrevail Partners
& 2 more
- Employee Count22
Products & Services of Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals offers a comprehensive portfolio of products and services, including Breakthrough Therapies.
Therapies are developed for blood diseases and infections.
Apps and channels of Hemogenyx Pharmaceuticals
its YouTube channel hemogenyx hemogenyx has 160 subscribers and 13 videos.
Videos from Hemogenyx Pharmaceuticals
The most watched videos on Hemogenyx Pharmaceuticals's YouTube channel, hemogenyx hemogenyx (160 subscribers). Click a video to play it here.
More on hemogenyx hemogenyx.
Funding Insights of Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals has successfully raised a total of $1M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.41 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1M
- Total Rounds 8
- Last Round Post-IPO — $3.41M
- First Round $250,000
(Oct 2014)
- Investors Count 3
All 8 funding rounds of Hemogenyx Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $3.41M | Post-IPO | – | – | – |
| Mar 2025 | $915,095 | Post-IPO | – | – | – |
| Jan 2025 | $425,598 | Post-IPO | – | – | – |
| Mar 2024 | $4.49M | Post-IPO | – | – | – |
| Sep 2023 | $830,000 | Post-IPO | – | – | |
| Nov 2020 | Post-IPO | – | – | ||
| Jun 2016 | $1M | Seed | – | – | – |
| Oct 2014 | $250,000 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Prevail Partners, MINT Capital and 43North.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Limited information is provided about Prevail Partners' activities. | prevailpartners.com | |||
Seed-stage investments are targeted by 43North in startups. | 43north.org | Buffalo, United States | ||
Offers secure software solutions for building platforms to clients. | 2005 | mintcap.co.uk | London, United Kingdom |
Investor details for Hemogenyx Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hemogenyx Pharmaceuticals
12 people are tracked at Hemogenyx Pharmaceuticals (2 in leadership, 5 in board & advisors, 5 in team); the tracked headcount is 22.
| Name | Role | Group |
|---|---|---|
Elina Shrestha | Director, Pre-Clinical Development | Leadership |
Vladislav Sandler | CEO & Co-Founder | Leadership |
Koen Van Besien | Clinical Advisor | Board & advisors |
H. Michael Shepard | Scientific Advisor | Board & advisors |
Peter Redmond | Non-Executive Director | Board & advisors |
Marc Feldmann | Chairman | Board & advisors |
Alexis M. Sandler | Non-Executive Director & Co-Founder | Board & advisors |
Cristine Chisholm | Scientist | Team |
Carina Sirochinsky | Associate Scientist | Team |
Ronen Ben Jehuda | Principal Scientist | Team |
Anugraha Babuji | Scientist | Team |
Michael Haugbro | Senior Scientist | Team |
Complete people profiles for Hemogenyx Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals is a publicly listed company on the LSE with ticker symbol HEMO in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Nov 2015
- Listed onLSE: HEMO
- Listed entityHemoGenyx Pharmaceuticals Plc
- Exchange sectorHealth technology
- ISINGB00BQVXM815
- Share price721.90 GBX (-6.25% on the day) · 2026-10-14
- Market capitalisation53,105,253.00 GBX
- EPS (diluted, trailing year)-1.80 GBX
- Volume (last session)8,114
Financials of Hemogenyx Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -9.8M GBP | -4.1M GBP | |
| 2024 | -5.6M GBP | -5.1M GBP | |
| 2023 | -6.7M GBP | -4.9M GBP | |
| 2022 | -4.0M GBP | -5.0M GBP | |
| 2021 | -5.1M GBP | -2.7M GBP |
Detailed financial statements for Hemogenyx Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Hemogenyx Pharmaceuticals
4 dated milestones of Hemogenyx Pharmaceuticals across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Hemogenyx Pharmaceuticals is founded.
- Funding First funding round of $250K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $3.4M.
Competitors of Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of Hemogenyx Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Hemogenyx Pharmaceuticals (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hemogenyx Pharmaceuticals
Complete news archive for Hemogenyx Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals was founded in 2014.
Hemogenyx Pharmaceuticals is headquartered in Buffalo, United States. It is registered at Buffalo, New York, United States.
Hemogenyx Pharmaceuticals is a funded company, having raised a total of $1M across 8 funding rounds to date. The company's 1st funding round was a Grant of $250K, raised on Oct 2014.
Hemogenyx Pharmaceuticals has 22 employees.
Hemogenyx Pharmaceuticals is focused on the development of innovative therapies for the treatment of life-threatening blood diseases and viral infections. Research and solutions are targeted at addressing critical medical needs in the healthcare sector, particularly in biotechnology. The company operates with facilities in both the United Kingdom and the United States to advance its pipeline of therapeutic products.
Hemogenyx Pharmaceuticals's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
Hemogenyx Pharmaceuticals offers Breakthrough Therapies.
Yes, Hemogenyx Pharmaceuticals is publicly traded on LSE under the ticker symbol HEMO.
Hemogenyx Pharmaceuticals has 3 investors. Key investors include Prevail Partners, MINT Capital, and 43North.
Hemogenyx Pharmaceuticals operates through Hemogenyx Pharmaceuticals Plc.